Lupin Q3 Results: PAT rises 39% YoY to ₹859 crore; EBITDA margin surges 408 bps to 25.1%

Sales for the quarter under review came in at ₹5,618.6 crore, up 10.6% against ₹5,079.9 crore registered in the December 2023 quarter.

EBITDA, or earnings before interest, taxes, depreciation, and amortisation, jumped 32.1% to ₹1,409.6 crore. It was ₹1,067.3 crore in the corresponding quarter of the previous fiscal year.

EBITDA margin zoomed 408 basis points (bps) to 25.1% from 21%.

Besides, the company stated that employee benefits cost was 17.5% of sales at ₹984.4 crore compared to ₹889.2 crore in Q3 FY2024.

Manufacturing and other expenses were at 30.2% of sales at ₹1,695.9 crore compared to ₹1,560.1 crore in Q3 FY2024.

Investment in R&D for the quarter was ₹434.4 crore (7.7% of sales).

Nilesh Gupta, Managing Director, Lupin Limited, said, “Our third-quarter results highlight our continued strength, with both revenue and EBITDA showing sustained growth. US revenues, led by building scale in new products, have been pivotal for our growth, supported by a strong nine-month performance from our India and EMEA regions. We look forward to maintaining this momentum in the ensuing quarters backed by growth in sales, commercial and operating efficiencies, and strong compliance.”

Balance Sheet Highlights as of December 31, 2024

• Operating working capital was ₹7,070.0 crore;

• Capital Expenditure for the quarter was ₹124.1 crore;

• Net Debt stands at ₹102.7 crore;

• Net Debt-Equity stands at 0.01.

Lupin's Sales Mix

About Lupin

Its other initiatives are Lupin Diagnostics, Lupin Digital Health, Atharv Ability, and Lupin Human Welfare and Research Foundation.

Lupin share price trend

Shares of Lupin Ltd have rallied 30% in the past 12 months.